immunoSEQ Blog

Adaptive Customers Publish Latest Results in The Journal of Experimental Medicine

Last week, a team of researchers from the University of Pittsburgh, Children’s Hospital of Pittsburgh, the University of Pennsylvania, Genentech, and the NIH published results from a study in which they used the immunoSEQ assay to explore fungal infections cased by Candida albicans. The study resulted in the findings that nTh17 and gamma delta T cells, but not… Read More→

Categorized in: Announcements |

Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer

SEATTLE, September 16, 2014 (PR NEWSWIRE) – Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer (CCO). The addition of Brian to the Company’s expanding Executive Leadership Team follows recent key hires… Read More→

Categorized in: Announcements |

Adaptive Biotechnologies CEO to give talk at University of Washington Today

Adaptive Biotechnologies CEO is speaking at the University of Washington today, September 12th at 12pm in a talked entitled “The Story of Adaptive Biotechnologies.”  In the presentation, Mr. Robins will describe the evolution of Adaptive Biotechnologies business from inception and provide advice and lessons learned to budding entrepreneurs. For more information, see here. Location: C4C… Read More→

Categorized in: Announcements |

Personalized Medicine: One Person ≠ One Genome

Can we be defined and biologically understood through the interpretation of a single human genome per person? We often refer to the human genome in a singular context with each person having their genome defined by roughly 3.1 billion base pairs.  Giving rise to the differences from one person’s genome to another, there may be… Read More→

Categorized in: Food for Thought |

New High-Dose Vaccine Flu Study Shows Positive Results

Newly released study results show that a high-dose flu vaccine significantly improved protection against flu among adults 65 and older. The finding is meaningful for public health. Seasonal flu caused an average of 36,000 deaths and 226,000 hospitalizations per year in the US between 1990 and 1999. Older adults, who are particularly vulnerable to complications… Read More→

Categorized in: Food for Thought |

What is that mysterious Ebola drug?

There has been a ton of press recently about an experimental drug – ZMapp – that has been given to a few Ebola patients.  What is it?  According to Mapp Biopharmaceutical’s FAQs, it is a cocktail of three monoclonal antibodies (mAb) that was developed very recently – January 2014.  The publication about ZMapp just came… Read More→

Categorized in: Food for Thought |

New Recommendations for Evaluation, Staging and Response Assessment of HL and NHL Published

Lymphoma diagnostic evaluation and monitoring is undergoing another revision within the biomedical community. An international group of clinical investigators has summarized the results of multiple workshops over the past three years in a recent publication “Recommendations for initial evaluation, staging, and response assessment of Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL): The Lugano Classification”, Journal of… Read More→

Categorized in: Food for Thought |

Adaptive CEO joins distinguished panel at Genomics 2.0 Conference to Discuss Company’s Pipeline of Cancer Diagnostics

“Changing the Game in Oncology” panel includes Invitae CEO Randy Scott, Foundation Medicine COO Steven Kafka, and Thermo Fisher Division President Ronnie Andrews PARK CITY, UT – Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, announced today that Chad Robins, its Founder and Chief… Read More→

Categorized in: Announcements |

Adaptive’s Latest Internal Publication Featured in FHCRC’s Science Spotlight

At the end of June this year, Adaptive employees along with investigators from UW, UCSF, Children’s National Medical Center, and FHCRC published a paper in Clinical Cancer Research titled ‘Detection of minimal residual disease in patients with B lymphoblastic leukemia by high-throughput sequencing of IGH‘. On August 18th, Fred Hutchinson Cancer Research Center did a… Read More→

Categorized in: Food for Thought |